For the quarter ending 2026-03-31, STOK made $6,229K in revenue. -$50,661K in net income. Net profit margin of -813.31%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 6,229 | 1,402 | 10,632 | 13,817 |
| Research and development | 39,673 | 41,695 | 37,696 | 25,855 |
| General and administrative | - | - | - | 15,262 |
| Sales, general and administrative | 19,974 | 21,146 | 16,027 | - |
| Total operating expenses | 59,647 | 62,841 | 53,723 | 41,117 |
| (loss) income from operations | -53,418 | -61,439 | -43,091 | -27,300 |
| Interest income (expense), net | 3,397 | 3,615 | 3,463 | 3,789 |
| Other income | 18 | -110 | 3 | 28 |
| Total other income (expense) | 3,415 | 3,505 | 3,466 | 3,817 |
| (loss) income before income taxes | -50,003 | - | -39,625 | -23,483 |
| Provision for income taxes | 0 | - | -1,278 | 0 |
| Net (loss) income | -50,003 | -57,934 | -38,347 | -23,483 |
| Unrealized (loss) gain on marketable securities | -658 | 97 | 350 | 200 |
| Total other comprehensive (loss) gain | -658 | 97 | 350 | 200 |
| Comprehensive (loss) income | -50,661 | -57,837 | -37,997 | -23,283 |
| Basic EPS | -0.79 | -0.932 | -0.65 | -0.4 |
| Diluted EPS | -0.79 | -0.956 | -0.65 | -0.4 |
| Basic Average Shares | 63,063,507 | 62,048,530 | 58,611,677 | 58,353,855 |
| Diluted Average Shares | 63,063,507 | 60,512,604 | 58,611,677 | 58,353,855 |
Stoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. (STOK)